HuGE Literature Finder
Records
1
-
19
| Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022 Sep . Momeni Boroujeni Amir, Kertowidjojo Elizabeth, Wu Xinyu, Soslow Robert A, Chiang Sarah, Da Silva Edaise M, Weigelt Britta, Chui M Herm |
| High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior. The American journal of surgical pathology 2017 Aug . Hodgson Anjelica, Amemiya Yutaka, Seth Arun, Djordjevic Bojana, Parra-Herran Carl |
| Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx. Scientific reports 2017 Jan 7 39765. Zhang Yang, Sturgis Erich M, Li Yuncheng, Wei Qingyi, Huang Zhigang, Li Guoj |
| Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. The Journal of urology 2016 Jan . Bagrodia Aditya, Cha Eugene K, Sfakianos John P, Zabor Emily C, Bochner Bernard H, Al-Ahmadie Hikmat A, Solit David B, Coleman Jonathan |
| Association of the recurrence of vocal leukoplakia with MDM2-309 variants over a 2-year period: a prospective study. Acta oto-laryngologica 2015 Sep 1-5. Zhou Jian, Yang Yue, Zhang Duo, Zhou Liang, Liu Fei, Tao Lei, Lu Li-Mi |
| A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 Apr 26 (4): 624-44. Findlay J M, Middleton M R, Tomlinson |
| Association between MDM2 SNP309 T>G polymorphism and the risk of bladder cancer: new data in a Chinese population and an updated meta-analysis. OncoTargets and therapy 2015 8 3679-90. Xie Linguo, Sun Yan, Chen Tao, Tian Dawei, Li Yujuan, Zhang Yu, Ding Na, Shen Zhonghua, Xu Hao, Nian Xuewu, Sha Nan, Han Ruifa, Hu Hailong, Wu Chang |
| Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer. International journal of molecular sciences 2014 15 (7): 12458-68. Salvi Samanta, Calistri Daniele, Gurioli Giorgia, Carretta Elisa, Serra Luigi, Gunelli Roberta, Zoli Wainer, Casadio Valenti |
| Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein & cell 2013 Jan 4 (1): 1. Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, Deng Q, Lan K, Zhou W |
| MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC urology 2013 13 (1): 5. Olsson Hans, Hultman Per, Rosell Johan, Söderkvist Peter, Jahnson Staff |
| Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. The Journal of investigative dermatology 2012 May 132 (5): 1471-8. Cotignola Javier, Chou Joanne F, Roy Pampa, Mitra Nandita, Busam Klaus, Halpern Allan C, Orlow Ire |
| Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. Journal of gastroenterology and hepatology 2012 Apr 27 (4): 797-804. Tomoda Takeshi, Nouso Kazuhiro, Sakai Akiko, Ouchida Mamoru, Kobayashi Sayo, Miyahara Koji, Onishi Hideki, Nakamura Shinichiro, Yamamoto Kazuhide, Shimizu Ken |
| Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA and cell biology 2010 Jul 29 (7): 349-56. Gangwar Ruchika, Mittal Rama De |
| p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urologia internationalis 2010 85 (4): 401-5. Xu Bin, Mi Yuan-Yuan, Min Zhi-Chao, Cheng Gong, Tong Na, Tao Jun, Li Peng-Chao, Wang Mei-Lin, Tang Jia-Lin, Zhang Zheng-Dong, Song Ning-Hong, Zhang Wei, Wu Hong-Fei, Feng Ning-Han, Hua Li-X |
| Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. The Journal of urology 2009 Apr 181 (4): 1907-12. Hirata Hiroshi, Hinoda Yuji, Kikuno Nobuyuki, Suehiro Yutaka, Shahryari Varahram, Ahmad Ardalan E, Tabatabai Z Laura, Igawa Mikio, Dahiya Rajv |
| Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncology reports 2008 Jul 20 (1): 49-55. Horikawa Yohei, Nadaoka Junichi, Saito Mitsuru, Kumazawa Teruaki, Inoue Takamitu, Yuasa Takeshi, Tsuchiya Norihiko, Nishiyama Hiroyuki, Ogawa Osamu, Habuchi Tomono |
| MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008 May 87 (2): 243-52. Tu Hsi-Feng, Chen Hong-Wen, Kao Shou-Yen, Lin Shu-Chun, Liu Chung-Ji, Chang Kuo-W |
| Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast cancer research : BCR 2007 9 (3): R34. Toyama Tatsuya, Zhang Zhenhuan, Nishio Mariko, Hamaguchi Maho, Kondo Naoto, Iwase Hirotaka, Iwata Hiroji, Takahashi Satoru, Yamashita Hiroko, Fujii Yoshita |
| No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urologic oncology 0 29 (3): 319-23. Jaboin Jerry J, Hwang Misun, Perez Carmen A, Cooper Calvin, Chen Heidi, Ye Chuanzhong, Cai Qiuyin, Wills Marcia L, Lu |
- Page last reviewed:Jul 25, 2022
- Page last updated:Nov 28, 2022
- Content source: